Did One Tiny Tweak Just Solve Heart Disease?

Summary of the Video’s Main Arguments and Reported Findings

• Heart disease might be “solvable” through a precise cholesterol mechanism. The video argues that if LDL cholesterol is the key driver of atherosclerotic cardiovascular disease (ASCVD), then permanently lowering LDL could dramatically reduce heart attack risk—potentially “rewriting” cardiovascular medicine.

• Large epidemiology and genetics studies point to LDL as causal.

  • It references the Framingham Heart Study and broader evidence identifying risk factors, emphasizing that LDL cholesterol is a pivotal ingredient for ASCVD.
  • It cites a European Atherosclerosis Society review (2017) covering 2+ million participants and 20 million person-years, concluding that LDL causes ASCVD.
  • It also discusses genetic evidence centered on PCSK9:
    • Families with overactive PCSK9 have sky-high LDL.
    • People with damaged/broken PCSK9 have substantially lower LDL and markedly lower lifetime coronary heart disease risk (including a Dallas Heart Study example).

• PCSK9 biology is linked not just to disease risk but potentially lifespan.

  • The video notes evidence (from 2021) that faulty PCSK9 variants may correlate with longer lifespan, strengthening motivation to target PCSK9.

Why Verve’s Approach Exists: Editing One “Letter” Instead of Cutting DNA

• The video explains CRISPR’s origins and why cutting DNA (CRISPR-Cas9) can be risky for therapy: cells repair double-strand breaks imperfectly, potentially causing large deletions or rearrangements.
• It cites an early cautionary tale from early 2000s SCID-X1 (“bubble boy”) gene therapy, where some patients developed T-cell leukemia after viral integration near LMO2.
• To avoid these risks, Verve uses base editing (attributed to David Liu):
  • Base editors perform a single DNA-letter swap (no double-strand breaks).
  • The therapy aims to permanently disrupt PCSK9 gene function, stopping PCSK9 protein production.

Safety Uncertainty Remains in Gene Editing Generally

• The video acknowledges ongoing concerns and cites an example from October 2025:
  • An 80-year-old in a different gene editing trial developed grade 4 liver injury and later died.
  • The FDA placed the trial on clinical hold.
• Because of uncertainty, base editing participants are described as requiring 15 years of mandatory follow-up.

Real-World Precedent for Base Editing

• The video mentions Alyssa Teapley, a UK teenager who received a base-editor treatment after refractory T-cell leukemia, reportedly entering remission within a month.
• It also notes she appeared with David Liu after Liu received a Breakthrough Prize (as shown in the video).

The Key Delivery Breakthrough: Improved Targeting to the Liver

• The video argues that delivery is crucial because base editing machinery is fragile and immunogenic.
• It describes lipid nanoparticles as the delivery vehicle and highlights a liver targeting advantage: the liver rapidly clears these particles.
• To improve selectivity, Verve’s updated formulation uses GalNAc (a sugar tag) to bind receptors enriched on liver cells.

Preclinical Proof-of-Concept (Animals)

• It cites Nature (2021) results in monkeys:
  • After one dose, PCSK9 production dropped ~90%
  • LDL fell ~60%
  • Effects persisted for up to 8 months

The Program’s Early Human Setback (April 2024) and Why It Was Changed

• During the initial human trial (Heart 1), the first Verve 101 formulation nearly derailed the program:
  • In the 0.5 mg/kg group, the 6th patient developed platelet crash and ALT elevation (~grade 3) within 4 days.
  • The patient was asymptomatic, and values reportedly normalized within days.
  • Investigation concluded the likely issue was the delivery “truck” (the lipid nanoparticle formulation), not the base editor itself.
• Verve halted the original formulation and redesigned the delivery system.

Updated Results: Verve 102 (Stronger LDL Lowering With Improved Safety, per the Video)

• With the new formulation (Verve 102, lipid nanoparticle + GalNAc), the trial restarted in spring 2024.
• The video reports:
  • 35 patients across 6 dose cohorts
  • Participants with familial/genetic high LDL and/or premature coronary artery disease, all on maximally tolerated statins, with ~half also on ezetimibe
  • Dosing escalated from 0.3 mg/kg to 1.0 mg/kg
  • At the top dose:
    • PCSK9 dropped ~88%
    • LDL dropped ~62%, from 128 mg/dL to 51 mg/dL
  • Effects persisted across follow-up windows up to 18 months for some patients
• Safety profile (as reported by the video so far):
  • No deaths
  • No serious dose-limiting effects
  • No withdrawals
  • Some liver enzyme increases that resolved (peaking around day 3–4, resolving by day 8)
  • The prior platelet crash from Verve 101 reportedly did not recur
• The video frames this as potentially transformative: a large LDL reduction on top of standard therapy from a single infusion.

What Remains Unknown Before Calling It a “Cure” for Heart Disease

• The video stresses these are early results with limited follow-up, so longer and larger studies are needed before concluding heart disease is effectively “ended.”
• It quotes the authors’ prediction that if such LDL reductions persist over 20 years, ASCVD risk could drop by more than 50% for many patients—but emphasizes the “if.”

Next Steps: Expanded Trials Planned

• It notes Lilly (which acquired Verve Therapeutics) plans a larger trial later this year to further evaluate Verve 102.

Practical Takeaway Offered by the Video

• Until long-term outcomes are proven, the video reiterates that diet and exercise remain foundational.
• It also suggests the viewer watch another video for an underrated LDL-lowering medication (mentioned but not specified in the subtitles).

---

Presenters or Contributors Mentioned

• Verve Therapeutics (company; program discussed)
• Lilly (acquirer; future trial mentioned)
• David Liu (base editing pioneer; described as inventor)
• Jennifer Doudna
• Emmanuelle Charpentier
• Katherine Boileau (PCSK9 discovery context)
• Helen Hobbs
• Jonathan Cohen
• Alyssa Teapley (patient case)
• The FDA (clinical hold mentioned)
• The New England Journal of Medicine (journal publication referenced)